カテゴリ： GlobalData, アメリカ, 企業調査

iBio Inc (IBIO)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：iBio Inc (IBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013243
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：51
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It uses its ibiolaunch platform, which is a transformative technology for the production of monoclonal antibodies, other therapeutic proteins and vaccines. iBio is developing therapeutic product for the treatment of idiopathic pulmonary fibrosis, systemic scleroderma and other fibrotic diseases, and others. The company’s IBIO-CFB03 is helpful for the treatment of idiopathic pulmonary fibrosis, fibrotic diseases and systemic sclerosis, among others. It collaborates with medical universities for its research and development activities. iBio is headquartered in New York, the US.

iBio Inc (IBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
iBio Inc, Medical Devices Deals, 2011 to YTD 2017 10
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
iBio Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
iBio Acquires Orphan Drug Designation And Related Property Rights From Kentucky Bioprocessing 13
Partnerships 14
Texas A&M University Enters into Agreement with iBio 14
iBio Amends Agreement with Medical University of South Carolina 15
iBio Amends Co-Development Agreement With Fraunhofer 16
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 17
iBio Enters into Agreement with Novici Biotech 18
Licensing Agreements 19
iBio Amends Licensing Agreement with US University 19
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 20
iBio Extends Licensing Agreement with Fraunhofer 21
iBio Extends its Licensing Agreement with Bio-Manguinhos 22
iBio Enters into Licensing Agreement with University of Pittsburgh 23
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 24
iBio Enters Into Licensing Agreement With Bio-Manguinhos 26
Equity Offering 27
iBio to Raise Funds in Public Offering of Shares 27
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 28
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 30
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 31
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 32
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 33
iBio Raises USD10 Million in Private Placemet of Shares 34
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 35
Ibio Completes Public Offering Of Units For US$4 Million 36
ibio Announces Private Placement Of Shares For Up To US$10 Million 37
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For US$10 Million 38
iBio Inc – Key Competitors 39
iBio Inc – Key Employees 40
iBio Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Legal and Regulatory 42
Nov 06, 2017: iBio Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court 42
Aug 15, 2016: Implications of Court Decision in Favor of iBio Against Fraunhofer 43
Aug 08, 2016: Delaware Chancery Court confirms Fraunhofer USA Rights 45
Aug 04, 2016: iBio’s Claims Against Fraunhofer Affirmed by Delaware Chancery Court 46
Product News 47
Sep 29, 2016: iBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies 47
Other Significant Developments 48
Oct 30, 2017: iBio CDMO President to Co-Chair South African Molecular Pharming Conference 48
May 04, 2017: iBio Provides Corporate Update at Annual Shareholders Meeting 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
iBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
iBio Inc, Deals By Therapy Area, 2011 to YTD 2017 9
iBio Inc, Medical Devices Deals, 2011 to YTD 2017 10
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
iBio Acquires Orphan Drug Designation And Related Property Rights From Kentucky Bioprocessing 13
Texas A&M University Enters into Agreement with iBio 14
iBio Amends Agreement with Medical University of South Carolina 15
iBio Amends Co-Development Agreement With Fraunhofer 16
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 17
iBio Enters into Agreement with Novici Biotech 18
iBio Amends Licensing Agreement with US University 19
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 20
iBio Extends Licensing Agreement with Fraunhofer 21
iBio Extends its Licensing Agreement with Bio-Manguinhos 22
iBio Enters into Licensing Agreement with University of Pittsburgh 23
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 24
iBio Enters Into Licensing Agreement With Bio-Manguinhos 26
iBio to Raise Funds in Public Offering of Shares 27
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 28
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 30
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 31
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 32
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 33
iBio Raises USD10 Million in Private Placemet of Shares 34
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 35
Ibio Completes Public Offering Of Units For US$4 Million 36
ibio Announces Private Placement Of Shares For Up To US$10 Million 37
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For US$10 Million 38
iBio Inc, Key Competitors 39
iBio Inc, Key Employees 40
iBio Inc, Subsidiaries 41

★海外企業調査レポート[iBio Inc (IBIO)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Portland General Electric Company：企業の戦略・SWOT・財務分析
    Portland General Electric Company - Strategy, SWOT and Corporate Finance Report Summary Portland General Electric Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • IPCA Laboratories Ltd (IPCALAB)：製薬・医療：M&Aディール及び事業提携情報
    Summary IPCA Laboratories Ltd (IPCA) is a pharmaceutical company which manufactures and markets active pharmaceutical ingredients, generics and formulations for various therapeutic areas. The company’s active pharmaceutical ingredients include anti-hypertensive, anti-malarial, diuretic and anthelmin …
  • Harvard Stem Cell Institute-製薬・医療分野：企業M&A・提携分析
    Summary Harvard Stem Cell Institute (HSCI), a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, cor …
  • Spineology Inc-医療機器分野：企業M&A・提携分析
    Summary Spineology Inc (Spineology) is a medical device company that develops and designs spinal implants. The company offers products such as pedicular fixation system, interbody fusion system, deployable grafting system, amniotic fixation system, allografts, retractor system, liquid tissue matrix, …
  • SELEX Galileo Inc.：企業の戦略・SWOT・財務分析
    SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report Summary SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Olympus Corporation (7733)-医療機器分野：企業M&A・提携分析
    Summary Olympus Corporation (Olympus) is a manufacturer of precision machineries and instruments. The company develops, manufactures and markets equipment and devices for medical, healthcare, imaging, information, and other industrial markets. It offers a wide range of products including digital SLR …
  • Hitachi Ltd (6501)：企業の財務・戦略的SWOT分析
    Hitachi Ltd (6501) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • A. Menarini Industrie Farmaceutiche Riunite Srl：企業の戦略的SWOT分析
    A. Menarini Industrie Farmaceutiche Riunite Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Immune Pharmaceuticals Inc (IMNP)：企業の財務・戦略的SWOT分析
    Summary Immune Pharmaceuticals Inc (Immune Pharma) formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designed …
  • Ethicon US LLC：医療機器：M&Aディール及び事業提携情報
    Summary Ethicon US LLC (Ethicon), a subsidiary of Johnson and Johnson, is a medical equipment company which operates through Ethicon Inc, and Ethicon Endo-Surgery Inc. It develops and markets surgical instruments and devices. Its major products include staplers, energy devices, clip appliers, trocar …
  • Triodos Bank NV：企業の戦略・SWOT・財務情報
    Triodos Bank NV - Strategy, SWOT and Corporate Finance Report Summary Triodos Bank NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Anixter International Inc (AXE)：電力：M&Aディール及び事業提携情報
    Summary Anixter International Inc. (Anixter), formerly Itel Corporation, is a distributor of network and security solutions, electrical and electronic solutions and utility power solutions. The company distributes communications, and electrical wire and cable products, fasteners and C Class inventor …
  • R1 RCM Inc (RCM)：企業の財務・戦略的SWOT分析
    R1 RCM Inc (RCM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bangkok Bank Public Co Ltd：戦略・SWOT・企業財務分析
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • DIAsource ImmunoAssays SA：企業の製品パイプライン分析2018
    Summary DIAsource ImmunoAssays SA (DIAsource), formerly BioSource Europe SA, a subsidiary of BioVendor - Laboratorni Medicina as, is a diagnostics company that develops, manufactures and markets clinical diagnostic products. The company’s products comprise immunoassays, antibodies, instruments and R …
  • Goteborg Energi AB：企業の発電所・SWOT分析2018
    Goteborg Energi AB - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Astrazeneca Pharma India Ltd (ASTRAZEN)：製薬・医療：M&Aディール及び事業提携情報
    Summary AstraZeneca Pharma India Ltd (AstraZeneca), a subsidiary of AstraZeneca Plc, is a biopharmaceutical company that discovers, develops, and commercializes medicines. The company offers products in the therapeutic areas of cardiovascular and metabolic diseases, respiratory, maternal healthcare, …
  • Bank Audi SAL：企業の戦略・SWOT・財務分析
    Bank Audi SAL - Strategy, SWOT and Corporate Finance Report Summary Bank Audi SAL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Theralase Technologies Inc (TLT)：企業の財務・戦略的SWOT分析
    Summary Theralase Technologies Inc (Theralase) is a clinical stage pharmaceutical company which specializes in design, development, and manufacturing of laser based technologies used in wide range of bio-destructive and bio-simulative clinical applications. The company is focused on the development …
  • Raiffeisen Group：企業の戦略・SWOT・財務情報
    Raiffeisen Group - Strategy, SWOT and Corporate Finance Report Summary Raiffeisen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆